Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fate Therapeutics (FATE) EBITDA Margin (2016 - 2025)

Fate Therapeutics' EBITDA Margin history spans 14 years, with the latest figure at 2367.49% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 46691.0% year-over-year to 2367.49%; the TTM value through Dec 2025 reached 2053.37%, down 68877.0%, while the annual FY2025 figure was 2053.37%, 68877.0% down from the prior year.
  • EBITDA Margin reached 2367.49% in Q4 2025 per FATE's latest filing, down from 1847.16% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 29.96% in Q1 2023 to a low of 5648.02% in Q2 2023.
  • Average EBITDA Margin over 5 years is 1466.55%, with a median of 1040.46% recorded in 2024.
  • Peak YoY movement for EBITDA Margin: tumbled -523486bps in 2023, then skyrocketed 507721bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 406.06% in 2021, then skyrocketed by 69bps to 123.92% in 2022, then plummeted by -2000bps to 2601.91% in 2023, then fell by -9bps to 2834.41% in 2024, then increased by 16bps to 2367.49% in 2025.
  • Per Business Quant, the three most recent readings for FATE's EBITDA Margin are 2367.49% (Q4 2025), 1847.16% (Q3 2025), and 1793.34% (Q2 2025).